An iridium( iii )-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
This is the first report of a metal complex that targets the BRD4-acylated histone protein-protein interaction (PPI).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [38]
Experimental — accuracy not yet measuredIn the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
The Role of Chromatin during Transcription
Li, B., Carey, M., & Workman, J. L. (2007) · Cell · doi:10.1016/j.cell.2007.01.015 · Cited by 3,533
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., & Patel, D. J. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1338 · Cited by 1,418
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., & Sims, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108190108 · Cited by 1,110
Research works printed but not linked: 3
- Florence, 2001, Front. Biosci., 6, d1008
- Chung, 2012, Drug Discovery Today: Ther. Strategies, 9, e111
- Chen, 2014, BioMed Res. Int., 2014, 232870
Cited by
Items 101–144 of 144
Wang, J., Kou, J., Zhao, Z., Qiu, K., & Chao, H. (2017) · Inorganic Chemistry Frontiers · doi:10.1039/c7qi00149e · Cited by 14
Inhibition of TLR1/2 dimerization by enantiomers of metal complexes
Liu, L., Wang, W., Zhong, Z., Lin, S., Lu, L., Wang, Y., Ma, D., & Leung, C. (2016) · Chemical Communications · doi:10.1039/c6cc06155a · Cited by 12
Self-citationBiological Significance of Hetero-Scaffolds Based Gold(III) Complexes
Kanthecha, D. N., Raval, D. B., Thakkar, V. R., & Patel, M. N. (2018) · Acta chimica slovenica · doi:10.17344/acsi.2017.4018 · Cited by 12
Mukherjee, S., Ghosh, S., Renuga Devi, M., Roy, S., Roy, S. S., Acharya, M., Kumar, B. K., & Mukherjee, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01150 · Cited by 11
Yu, Y., & Xia, J. (2016) · Science China Chemistry · doi:10.1007/s11426-016-5571-6 · Cited by 11
Synthesis and Biological Investigation of (+)-JD1, an Organometallic BET Bromodomain Inhibitor
Hassell‐Hart, S., Runcie, A. C., Krojer, T. J., Doyle, J., Lineham, E., Ocasio, C. A., Neto, B. A. D., Fedorov, O., Marsh, G. P., Maple, H. J., et al. (2019) · Organometallics · doi:10.1021/acs.organomet.9b00750 · Cited by 11
Lam, Y.-Y., Lee, N.-S., Lee, S.-F., & Chung, C. Y. (2023) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2023.122982 · Cited by 10
Ramachandran, V., Padmanaban, E., Ponnusamy, K., Subbarao, N., & Manoharan, N. (2016) · RSC Advances · doi:10.1039/c5ra24999f · Cited by 10
Pradhan, K. C., Jadab, M., Rout, S., Dandela, R., Mandal, D., Parija, T., Barik, S., Kumar, J., & Pal, S. (2023) · Zeitschrift für anorganische und allgemeine Chemie · doi:10.1002/zaac.202300169 · Cited by 9
Direct Targeting of Gene Regulators by Iridium(III) and Rhodium(III) Complexes
Wu, L., Kong, L., Wang, W., & Leung, C. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00570 · Cited by 9
Self-citationChen, J., Guo, X., Li, D., Tang, H., Gao, J., Yu, W., Zhu, X., Sun, Z., Huang, Z., & Chen, L. (2023) · Metallomics · doi:10.1093/mtomcs/mfad035 · Cited by 9
Kumar, Y. P., Devi, C. S., Srishailam, A., Deepika, N., Vuradi, R. K., Reddy, P. V., Kotikalapudi, N., Singh, S. S., Nagababu, P., & Satyanarayana, S. (2016) · Journal of Fluorescence · doi:10.1007/s10895-016-1908-y · Cited by 9
Zhang, J., Li, W., Huang, Y., Qin, Z.-Q., & Li, H. (2023) · Dyes and Pigments · doi:10.1016/j.dyepig.2023.111922 · Cited by 8
Deng, L., Tian, E., Ma, T., Liang, S., Hu, S., Li, L., & Li, J. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102670 · Cited by 7
Luminescent Strategies for Label‐Free G‐Quadruplex‐Based Enzyme Activity Sensing
Ma, D., Dong, Z., Vellaisamy, K., Cheung, K., Yang, G., & Leung, C. (2017) · The Chemical Record · doi:10.1002/tcr.201700014 · Cited by 7
Self-citationLi, J., Chen, C., Huang, J. Y., Wang, L., Xu, Z., Kang, W., Lin, M., & Wang, H. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3425147 · Cited by 7
“To identify the phase distribution of cellular DNA, cell cycle analysis was performed as described [17].”
MethodLiu, M., Zhang, R., Wang, J., Zhang, H., Tan, J., Liu, Q., Han, L., & Lu, L. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c01779 · Cited by 6
Self-citationBiological Applications of Supramolecular Coordination Complexes
Leung, C., Kang, T., Yang, C., Leung, K., & Ma, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12558-2 · Cited by 6
Self-citationCrystal structure and thermal properties of K3[Ir(C2O4)3]·4.25H2O and K3[Ir(C2O4)3]·0.5KCl·4H2O
Kochetygov, I., Filatov, E. Y., Kuratieva, N. V., Plyusnin, P. E., Naumov, D. Y., Zadesenets, A. V., Korenev, S. V., Tsygankova, A. R., & Логвиненко, В. А. (2016) · Journal of Thermal Analysis and Calorimetry · doi:10.1007/s10973-016-5687-0 · Cited by 5
“plexes are shown to bind to DNA and/or perturb the redox balance in cell [6, 7].”
BackgroundRuthenium, Osmium and Iridium in the Fight Against Cancer
Romero‐Canelón, I. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016452-00031 · Cited by 5
Arakelyan, J., Rusanov, D. A., Chang, M. R., Asaturova, A. V., Kireeva, G. S., Alshehri, M. M., Ang, W. H., & Babak, M. V. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214899 · Cited by 5
Domain structure of CoIr nanoalloys
Filatov, E. Y., Cherepanova, S. V., Kochetygov, I., Shubin, Y. V., & Korenev, S. V. (2017) · Powder Diffraction · doi:10.1017/s0885715617000367 · Cited by 4
Acidity-responsive phosphorescent metal complexes for cancer imaging and theranostic applications
Liang, H., Zhong, Y., Tan, C., & Mao, Z. (2021) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2021.121821 · Cited by 4
Virtual Screening of Antitumor Inhibitors Targeting BRD4 Based on Machine Learning Methods
Wu, K., Zhang, C., He, B., Li, H., Tang, S., Tao, H., & Li, B. (2022) · ChemistrySelect · doi:10.1002/slct.202104054 · Cited by 4
Banerjee, S., De, S., Kumar, S. K. A., Bose, S., & Banerjee, S. (2025) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2025.113080 · Cited by 2
Tang, X., Fan, K., Qü, B., & Lu, L. (2019) · Microchimica Acta · doi:10.1007/s00604-019-3895-6 · Cited by 2
“These solvent complexes almost show no luminescence in aqueous solution, but they can selectively re-coordinate with His via replacing solvent molecules to form a new luminophore with strong luminescence [31, 32].”
BackgroundSelf-citationSingh, H., Singh, A., Gupta, M. K., Sharma, S., & Bedi, P. M. S. (2017) · Indian Journal of Pharmaceutical Sciences · doi:10.4172/pharmaceutical-sciences.1000294 · Cited by 2
“There are various enzymes present in our body having contributory effect in diverse disease conditions[4-8].”
Hu, M., Chen, S., Zhen, Y., Wang, X., Zhong, Y., Liang, X., Chong, C., & Zhong, H. (2025) · Pharmaceuticals · doi:10.3390/ph18081105 · Cited by 1
“Notably, BRD4 is highlighted due to its key role as an acetyltransferase in histone epigenetic modification, a primary focus of our group’s cancer drug development efforts [16].”
Self-citationMilović, L., Stefanović, M. M., Milović, E., Janković, N., & Simović, A. R. (2025) · Journal of Coordination Chemistry · doi:10.1080/00958972.2025.2603928 · Cited by 1
Jadab, M., Behera, S., Sahoo, A., Santra, M. K., Mallik, S., Kumar, J., & Pal, S. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.145540 · Cited by 1
Tapping the Potential of Marine Resources in the Arena of Cosmetics
Dangar, K. G., Changela, D. B., & Chauhan, K. S. (2020) · Springer eBooks · doi:10.1007/978-981-15-5017-1_19 · Cited by 1
Probing BRD Inhibition Substituent Effects in Bulky Analogues of (+)‐JQ1
Hassell‐Hart, S., Picaud, S., Lengacher, R., Csucker, J., Millet, R., Gasser, G., Alberto, R. A., Maple, H. J., Felix, R. L., Lesnikowski, Z. J., et al. (2021) · Helvetica Chimica Acta · doi:10.1002/hlca.202000214 · Cited by 1
“As a positive control, we also synthesised the reported iridium-containing BRD4 inhibitor 3a.[20]”
MethodGraf, M., Böttcher, H., Mayer, P., Metzler‐Nolte, N., Thavalingam, S., & Czerwieniec, R. (2022) · Zeitschrift für anorganische und allgemeine Chemie · doi:10.1002/zaac.202200047 · Cited by 1
Phosphorescent metal complexes for biomedical applications
Liu, J., Guan, R., Lin, X., Chen, Y., & Chao, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823144-9.00061-3
Yang, J., Wang, F., Huang, S., Feng, T., Xiong, K., Chen, Y., & Chao, H. (2025) · Angewandte Chemie · doi:10.1002/ange.202505689
Linker attachment points: “finishing touch” in PROTAC design
jiang, Q., Shi, H.-S., Zhao, C.-S., Wang, Z.-Y., Yu, M.-M., Zhang, X.-Y., & Liu, C.-J. (2026) · RSC Medicinal Chemistry · doi:10.1039/d6md00346j
Anticancer‐Active Organoiridium(III) Complexes With Schiff Base and Oxime Ligands: A Concise Review
Jadab, M., & Pal, S. (2026) · ChemistrySelect · doi:10.1002/slct.74150
Astapczuk, J., Szewczyk-Roszczenko, O. K., Vassetzky, Y. S., & Czarnomysy, R. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108449
BindingDB (2022) · UC San Diego · doi:10.7270/q22j6gkf
Metadata
- Authors
- Zhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H.
- Affiliations
- University of Macau (MO)
- Hong Kong Baptist University (HK)
- Chinese Academy of Sciences (CN)
- Hong Kong Polytechnic University (HK)
- Department of Fragrance and Cosmetic Science
- Corresponding author
- Ma, Dik-Lung
- Cai, Zongwei
- Leung, Chung-Hang
- ORCID
- Venue
- Chemical Science
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2015
- Volume
- 6
- Issue
- 10
- Pages
- 5400-5408
- ISSN
- 2041-6520 (ISSN-L)
- 2041-6539
- PMC
- PMC5510529
- OpenAlex
- W4247705075
- Cited by
- 138
- References
- 59
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 3 · 2023: 7 · 2022: 8 · 2021: 8 · 2020: 15 · 2019: 11 · 2018: 12 · 2017: 30 · 2016: 27 · 2015: 4
- FWCI
- 10.72
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Chemical Science (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HKBU Institutional Repository (Hong Kong Baptist University) (submittedVersion, other-oa)
- PolyU Institutional Research Archive (Hong Kong Polytechnic University) (submittedVersion)
- Funders
- Hong Kong Baptist University (FRG2/14-15/004)
- Health and Medical Research Fund (HMRF/13121482, HMRF/14130522)
- Science and Technology Development Fund (103/2012/A3, 098/2014/A2)
- Universidade de Macau (MYRG091(Y3-L2)-ICMS12-LCH, MYRG2015-00137-ICMS-QRCM, MRG023/LCH/2013/ICMS)
- The Research Grants Council, University Grants Committee, Hong Kong (HKBU/201811, HKBU/204612, HKBU/201913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- iridium(III) complexes, BRD4, protein-protein interaction inhibitors, epigenetic inhibitors, anticancer agents, melanoma, metal-based anticancer agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.